ArfGAP with GTPase domain, ankyrin repeat and PH domain 7, pseudogeneGenealiases: AGAP-7 · AGAP7 · CTGLF4 · bA109G10.1
Q-omics provides the consensus-scored AGAP7P profile across patient tissues and cancer cell-line models. AGAP7P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, AGAP7P is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, AGAP7P RNA expression shows 11,403 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, KIRC, and THYM as cancer lineages where AGAP7P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AGAP7P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AGAP7P survival associations across molecular data types. AGAP7P RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AGAP7P RNA expression–survival associations across cancer types. High AGAP7P expression shows unfavorable associations in KIRC and COAD, but favorable associations in BLCA, SKCM, HNSC and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for AGAP7P RNA expression.
This table summarizes AGAP7P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for AGAP7P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AGAP7P shows lower tumor expression in COAD and higher tumor expression in KIRC, LIHC, LUSC and ESCA. The KIRC box plot shows higher AGAP7P RNA expression in tumor versus normal tissue (log2 FC = +0.104, t-test p = .038).
This table shows molecular features associated with AGAP7P in patient tissues and cancer cell lines. In patient samples, AGAP7P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, AGAP7P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS.
